MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers by Schuff, N. et al.
BRAIN
A JOURNAL OF NEUROLOGY
MRI of hippocampal volume loss in early
Alzheimer’s disease in relation to ApoE
genotype and biomarkers
N. Schuff,
1,2 N. Woerner,
1 L. Boreta,
1 T. Kornﬁeld,
1 L. M. Shaw,
3 J. Q. Trojanowski,
3
P. M. Thompson,
4 C. R. Jack Jr,
5 M. W. Weiner
1,2; the Alzheimer’s Disease Neuroimaging
Initiative

1 Department of Veterans Affairs Medical Center, San Francisco, CA, USA
2 Department of Radiology, University of California, San Francisco, CA, USA
3 Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
4 Laboratory of Neuro Imaging, Department of Neurology, UCLA School of Medicine, Los Angeles, CA, USA
5 Mayo Clinic College of Medicine, Rochester, MN, USA
Data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (www.loni.ucla.
edu\ADNI). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not
participate in analysis or writing of this report. ADNI investigators include (complete listing available at www.loni.ucla.edu\ADNI\Collaboration\
ADNI_Manuscript_Citations.pdf).
Correspondence to: Norbert Schuff,
4150 Clement St 114M,
San Francisco, CA 94121, USA
E-mail: norbert.schuff@ucsf.edu
Hippocampal volume change over time, measured with MRI, has huge potential as a marker for Alzheimer’s disease. The
objectives of this study were: (i) to test if constant and accelerated hippocampal loss can be detected in Alzheimer’s disease,
mild cognitive impairment and normal ageing over short periods, e.g. 6–12 months, with MRI in the large multicentre setting
of the Alzheimer’s Disease Neuroimaging Initiative (ADNI); (ii) to determine the extent to which the polymorphism of the
apolipoprotein E (ApoE) gene modulates hippocampal change; and (iii) to determine if rates of hippocampal loss correlate with
cerebrospinal ﬂuid (CSF) biomarkers of Alzheimer’s disease, such as the b-amyloid (Ab1–42) and tau proteins (tau). The MRI
multicentre study included 112 cognitive normal elderly individuals, 226 mild cognitive impairment and 96 Alzheimer’s disease
patients who all had at least three successive MRI scans, involving 47 different imaging centres. The mild cognitive impairment
and Alzheimer’s disease groups showed hippocampal volume loss over 6 months and accelerated loss over 1 year. Moreover,
increased rates of hippocampal loss were associated with presence of the ApoE allele e4 gene in Alzheimer’s disease and lower
CSF Ab1–42 in mild cognitive impairment, irrespective of ApoE genotype, whereas relations with tau were only trends. The power
to measure hippocampal change was improved by exploiting correlations statistically between successive MRI observations.
The demonstration of considerable hippocampal loss in mild cognitive impairment and Alzheimer’s disease patients over only
6 months and accelerated loss over 12 months illustrates the power of MRI to track morphological brain changes over time in
a large multisite setting. Furthermore, the relations between faster hippocampal loss in the presence of ApoE allele e4 and
decreased CSF Ab1–42 supports the concept that increased hippocampal loss is an indicator of Alzheimer’s disease pathology
and a potential marker for the efﬁcacy of therapeutic interventions in Alzheimer’s disease.
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Introduction
Alzheimer’s disease is the most common cause of dementia and a
growing health problem globally, affecting 20% of the population
over 80 years of age (Ferri et al., 2005). Currently, the deﬁnite
diagnosis of Alzheimer’s disease can only be made through
autopsy to ﬁnd the pathological hallmarks of the disease, micro-
scopic amyloid plaques and neuroﬁbrillary tangles. The develop-
ment of biomarkers that can reliably indicate presence of the
disease at the earliest possible stage is therefore an important
public health goal. Macroscopically, Alzheimer’s disease is asso-
ciated with progressive brain tissue loss (Braak and Braak, 1998),
which MRI can non-invasively visualize to some extent in-vivo
(Thompson et al., 2007). Not surprisingly, MRI has attracted
considerable interest as a tool to identify Alzheimer’s disease
biomarkers.
Histological studies have shown that the hippocampus is par-
ticularly vulnerable to Alzheimer’s disease pathology and already
considerably damaged at the time clinical symptoms ﬁrst appear
(Braak and Braak, 1998). The hippocampus has therefore become
a primary target of MRI studies in Alzheimer’s disease. In
agreement with histological ﬁndings, longitudinal MRI studies
have shown increased rates of hippocampal volume loss in
Alzheimer’s disease (Jack Jr et al., 2000, 2008b;D uet al., 2004;
Jack et al., 2004; Fox et al., 2005; Hashimoto et al., 2005; van de
Pol et al., 2005) and mild cognitive impairment (MCI, a transi-
tional stage to Alzheimer’s disease that may deﬁne a window for
effective therapeutic intervention) (Jack et al., 2005; van de Pol
et al., 2007), in comparison to normal ageing. Several MRI studies
also found that the apolipoprotein E gene allele e4 (ApoE4), a
major risk factor for Alzheimer’s disease, is associated with
higher rates of hippocampal loss (Moffat et al., 2000; Jack Jr
et al., 2008b; van de Pol et al., 2007), though the mecha-
nism behind the ApoE4 induced variations remains obscure.
Longitudinal MRI studies at multiple time-points further indicate
that brain loss in general (Chan et al., 2003; Carlson et al., 2008)
and hippocampus loss in particular (Ridha et al., 2006; Jack
et al., 2008c) accelerate in patients with MCI and Alzheimer’s
disease though the speciﬁc trajectory of change remains unknown.
To link MRI observations of hippocampal loss more ﬁrmly to the
presence of Alzheimer’s disease pathology, there has also been
growing interest in using MRI together with biochemical markers
of Alzheimer’s disease in CSF, such as the proteins of tau (indica-
tive of tangle formation) and amyloid Ab1–42 (a major component
of amyloid plaques) (Clark et al., 2008). Lastly, clinical trials of
Alzheimer’s disease and mild cognitive impairment have used the
progression of hippocampal loss as a potential surrogate for the
efﬁcacy of therapeutic interventions (Jack Jr et al., 2003, 2008b).
Despite many promising results, several technical issues in mea-
suring hippocampal disease progression remain unresolved, such
as data variability due to non-uniform acquisition and image
restoration processing. In this study, MRI was performed using
uniform imaging sequences and a centralized setup for quality
control and image restorations (Jack et al., 2008a). Furthermore,
the vast majority of longitudinal MRI studies were carried out over
a period of at least 1 year or much longer to ensure that the
accumulated hippocampal loss exceeded the incurred measure-
ment errors. Most studies were also performed at a single site
to avoid site-to-site variations in MRI. However, studies over a
long period at a single research centre represent a ‘best-case’
scenario, which can rarely be achieved in large studies, such as
clinical trials, involving several hundred subjects. The power of
MRI to measure hippocampal loss, especially acceleration, over
short periods and in a multisite setting remains to be determined.
Another issue is that many MRI investigations of biological effects
on hippocampal change involved only a small number of subjects,
especially those which involved CSF biomarkers, raising concerns
about the generalization of the ﬁndings. Lastly, few studies so far
reported ﬁndings of hippocampal changes, ApoE and CSF bio-
markers together (Hampel et al., 2005; de Leon et al., 2006;
Fjell et al., 2008). Although it was found that CSF biomarker
levels and the ApoE proﬁle are associated with morphometric
changes in the hippocampus, the extent to which each factor
independently contributes to the progression of hippocampal
changes has not been investigated.
The ongoing Alzheimer’s disease Neuroimaging Initiative (ADNI)
study has been designed to address these issues (Mueller et al.,
2005) (see also http://www.loni.ucla.edu/ADNI and http://
www.ADNI-info.org). The ADNI is a large multisite longitudinal
MRI and FDG-PET (ﬂuorodeoxyglucose positron emission tomo-
graphy) study of 200 cognitively normal (normal) elderly controls,
400 subjects with MCI and 200 patients diagnosed with
Alzheimer’s disease. At the time of writing this report, data col-
lection for the ADNI project is still in progress. Here, we report an
initial analysis of rates of hippocampal loss in 498 subjects, who
completed three successive MRI scans and clinical evaluations at
baseline, 6 and 12 months, involving 47 MRI sites.
Our main objectives in this study were: ﬁrst, to determine if
the rigorous methods of the ADNI to control site-to-site variations
in MRI allow the detection of hippocampal change, including
acceleration, over a short period, e.g. 6–12 months; second, to
determine the extent to which the ApoE genotype modulates
rates of hippocampal loss; and third, to test if rates of hippo-
campal loss correlate with CSF biomarkers.
Methods
Data used in the preparation of this article were obtained from the
ADNI database (www.loni.ucla.edu\ADNI). The ADNI was launched in
2003 by the National Institute on Aging (NIA), the National Institute
of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug
Administration (FDA), private pharmaceutical companies and non-
proﬁt organizations, as a $60 million, 5-year public–private partner-
ship. The primary goal of ADNI has been to test whether serial MRI,
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clinical and neuropsychological assessment can be combined to
measure the progression of MCI and early Alzheimer’s disease.
Determination of sensitive and speciﬁc markers of very early
Alzheimer’s disease progression is intended to aid researchers and
clinicians to develop new treatments and monitor their effectiveness,
as well as lessen the time and cost of clinical trials. The Principle
Investigator of this initiative is Michael W. Weiner, MD, VA Medical
Center and University of California, San Francisco. ADNI is the result
of efforts of many co-investigators from a broad range of academic
institutions and private corporations, and subjects have been recruited
from over 50 sites across the US and Canada. For up-to-date infor-
mation see www.adni-info.org.
Subjects
The study reported here involved 498 subjects who had MRI scans
at baseline, 6 and 12 months (0–6–12m) and hippocampal volume
change measured. Of those subjects, 11 were excluded because they
had lumbar puncture procedures within 510 days prior to their
MRI (a protocol violation), which may have induced artiﬁcial volume
changes of the brain. The MRI data of an additional 38 subjects were
excluded for technical reasons, such as major hardware upgrades
during the study (at two sites), miscalibration of image resolution or
failure to register images to a brain template for tracing the hippo-
campus. At the end, 127 normal, 226 MCI and 96 Alzheimer’s disease
subjects were considered. The main demographical and clinical data
of this group are summarized in Table 1. Consent was obtained
according to the Declaration of Helsinki (Br Med J 1991; 302: 1194)
and the Ethical Committees of each Institution in which the work
was performed approved the study.
All subjects underwent thorough clinical and cognitive assessments
at the time of each of their MRI scans. Each subject’s cognitive eval-
uation included: (i) the Mini-Mental State Examination (MMSE)
(Folstein et al., 1975) to provide a global measure of mental status;
(ii) the Alzheimer’s disease Assessment Scale-Cognitive Subscale
(ADAS-Cog) (Mohs et al., 1997), which is the most used cognitive
assessment battery in clinical dementia trials; and (iii) the Clinical
Dementia Rating (CDR) sum-of-boxes scale (sum of individual CDR
scales) (Morris, 1993) to stage severity of dementia. All subjects were
also examined for depression using the Geriatric Depression Scale
(GDS) questionnaire (Yesavage et al., 1982), in which subjects are
asked to respond to 30-items with ‘yes’ or ‘no’ in reference to how
they felt over the past week. More details about all the tests can be
found on the ADNI website www.loni.ucla.edu/ADNI.
The normal subjects had on average MMSE scores of 29.10.9,
ADAS-Cog scores of 6.13.3, CDR sum of boxes scores of 00.1
and GDS scores of 0.81.3. The MCI subjects had mild memory
complaints, but had no symptoms of dementia. On average, they
had MMSE scores of 26.91.8, ADAS-Cog scores of 11.64.5,
CDR sum of boxes scores of 1.60.9 and GDS scores of 1.51.3.
All Alzheimer’s disease patients met NINCDS/ADRDA criteria for prob-
able Alzheimer’s disease (McKhann et al., 1984). On average, they
had MMSE scores of 23.31.9 and ADAS-Cog scores of 17.95.6,
CDR sum of boxes scores of 4.41.5 and GDS scores of 1.71.3.
As such, these patients would be considered as having mild to
moderate, but not severe Alzheimer’s disease and no depression.
All subjects had their blood ApoE genotype determined. In addition,
two-third of the subjects had lumbar puncture procedures performed
for the collection of speciﬁc Alzheimer’s disease biomarkers. The deter-
minations of ApoE and biomarkers were performed by Drs Leslie Shaw
and John Trojanowski of the ADNI Biomarker Core at the University of
Pennsylvania School of Medicine, which collects and banks biological
samples (DNA, blood, urine and CSF) from all participating sites, and
conducts studies of selected Alzheimer’s disease biomarkers, including
total tau (t-tau), hyperphosphorylated tau (p-tau), b-amyloid-1–42
(Ab1–42), isoprostanes and homocysteine levels (Shaw et al., 2007;
Vanderstichele et al., 2008; Shaw et al., 2009) (see http://
www.adni-info.org/for more details).
Detailed exclusion criteria, e.g. regarding concomitant cerebral vascu-
lar disease or concurrent use of psychoactive medications, can be found
in the ADNI protocol (page 29, http://www.adni info.org/images/
stories/Documentation/adni_protocol_03.02.2005_ss.pdf). Brieﬂy, subj-
ects were excluded if they had any signiﬁcant neurological disease
other than incipient Alzheimer’s disease, any history of signiﬁcant brain
lesions or head trauma, or psychoactive medication use (including anti-
depressants, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.).
MRI acquisition and pre-processing
All subjects had MRI at 1.5T. The data were collected at multiple ADNI
sites using a standardized MRI protocol (http://www.loni.ucla.edu/
ADNI/Research/Cores/index.shtml), which was developed after a
major effort evaluating and comparing 3D T1-weighted sequences
for morphometric analyses (Jack et al., 2008a). In this study, the
MRI data came from 47 centres. Details of MRI acquisition and
Table 1 Group demographics and clinical data at baseline
Measures Normal Mild cognitive impairment Alzheimer’s disease P-value
n 127 226 96 NA
Women (%) 48 38 47 NS
Age (years) 76.35.1 75.07.1 75.86.6 NS
MMSE
a 29.10.9 26.91.8 23.31.9 50.001
ADAS-Cog
b 6.13.3 11.64.5 17.95.6 50.001
CDR Sum-of-boxes
c 00.1 1.60.9 4.41.5 50.001
GDS
d 0.81.3 1.51.3 1.71.4 50.001

ApoE4 carriers (%) 26 52 67 50.001
a Mini-Mental State Examination; range 0–30 points.
b Alzheimer’s disease Assessment Scale—Cognitive Subscale; range 0–70 points.
c Clinical Dementia Rating Scale; range 0–18 points.
d Geriatric Depression Scale; range 0–15 points.
Signiﬁcant difference in GDS scores between normal and mild cognitive impairment or Alzheimer’s disease.
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Jack et al., 2008a). Brieﬂy, for each subject, two T1-weighted MRI
scans were collected using a sagittal volumetric magnetization pre-
pared rapid gradient echo (3D MP-RAGE) sequence with the following
acquisition parameters: echo time (TE) of 4ms, repetition time (TR)
of 9ms, ﬂip angle of 8, acquisition matrix size of 256256166
in the x-, y- and z-dimensions with a nominal voxel size of
0.940.941.2mm. The ADNI MRI quality control centre at the
Mayo Clinic (Rochester, MN, USA) selected the MP-RAGE image
with higher quality based on standardized criteria (Jack Jr et al.,
2008b). To enhance the standardization across MRI sites and scanner
platforms, each site used the same customized imaging sequence for
volumetric brain morphometry, which was developed and tested on
phantoms and on 137 subjects during the preparation phase of the
ADNI study. Second, each subject scan was accompanied by a scan of
a custom built phantom that was centrally evaluated for signal-to-
noise and geometrical ﬁdelity to ensure performance of the MRI scan-
ners remained within a speciﬁc tolerance limit. More details about MRI
standardization in the ADNI study can be found in reference (Jack
et al., 2008a). Furthermore, system speciﬁc corrections of certain
image artefacts were performed centrally at the Mayo Clinic. The
corrections included: (i) a ‘B1-Field correction’ to adjust for inhomo-
geneity of image intensity induced by non-uniform radiofrequency
(RF) excitation using B1 calibration scans, (ii) ‘N3 bias ﬁeld correction’
to further reduce intensity inhomogeneity caused by non-uniform
sensitivity of the receiver coils, (iii) a geometrical distortion correction
to offset non-linearity in frequency encoding of magnetic ﬁeld gradi-
ents and (iv) global geometrical scaling, based on phantom mea-
surements that accompanied every subject’s MRI scan to adjust for
gradient calibration errors and drifts.
Hippocampal volume estimation
Tracing of the anatomical boundaries of the left and right hippo-
campus was performed using a semi-automated brain mapping
method based on a high-dimensional ﬂuid transformation algorithm
(Christensen et al., 1997), which combines a coarse and then a ﬁne
transformation of a carefully marked hippocampal MRI template from
a reference brain to match the target images of each subject. A com-
mercially available version of the algorithm was used (Medtronic
Surgical Navigation Technologies, Louisville, CO). To guide the initial
transformations, 22 control points are manually placed as rough local
landmarks for hippocampal segmentation: one point at the hippocam-
pal head, one at the tail, and four per image (i.e. at the superior,
inferior, medial and lateral boundaries) on ﬁve equally spaced image
slices perpendicular to the long axis of the ipsilateral hippocampus.
The last step is repeated for the contralateral hippocampus. Using
the landmarks for initial guidance, automated hippocampal segmen-
tation is then performed by the iterative ﬂuid transformation image
matching algorithm. The procedure has previously been validated
for hippocampal volume measurements in elderly subjects, including
mild cognitive impairment and Alzheimer’s disease patients (Hsu
et al., 2002).
To minimize measurement variability and bias from manually placing
the landmarks, a comprehensive procedure for assessing reader relia-
bility was implemented. First, the readers were extensively trained and
their reliability was evaluated by having each reader perform twice
volume measurements of a ‘gold standard’ MRI dataset that consisted
of 10 randomly selected subjects. To qualify, a reader had to achieve
an intraclass correlation coefﬁcient of at least 0.9 for both within and
between reader consistencies. Furthermore, reliability of readings was
monitored over time by blindly having each reader re-evaluate
randomly selected sets from the ‘gold-standard’ sets as data processing
progressed. The re-evaluations had to be within the 95% conﬁdence
limits to qualify. If a reader’s performance dropped outside the limits,
the last hippocampal markings by this reader were re-processed by a
qualiﬁed reader. In addition, the disqualiﬁed reader had to complete
training again to qualify.
Statistics
We employed a general linear mixed effects model for analysis of the
longitudinal data in which the response variable (e.g. hippocampal
volume or ADAS-Cog score) is regressed against the explanatory vari-
able (time) separately from within subject correlations. To investigate
the beneﬁts of collecting data at more than two time-points, we
extended the model by a transitional (i.e. Markov chain) model, in
which past observations explicitly inﬂuence present measurements.
More details are provided in the appendix. Other explanatory vari-
ables, e.g. diagnosis, age or ApoE4 proﬁle, were added into the
model as appropriate. To determine if the addition of explanatory
variables, especially the inclusion of past observations in the Markov
chain model, improved explanatory power, we designed paired models
(with and without the additional explanatory variable), ﬁtted the
models by maximum likelihood (ML) and compared the resulting ﬁts
via F-tests. The level of signiﬁcance was 0.05 for all tests.
To assess site-to-site variations in the MRI data, we bootstrapped
the random effects residuals of the ﬁts (i.e. the unexplained within-
person variation and noise) and evaluated differences between the
MRI centres by analysis of variance. To reduce the inﬂuence of
group heterogeneity between centres, we ﬁrst limited the analysis to
mild cognitive impairment patients, which was usually the group with
the most completed scans at each centre and second, we augmented
bootstrapping by permutation tests.
Sample size calculations for the number of subjects needed in a
hypothetical clinical trial of measuring a meaningful drug effect
(i.e. slowing of rates of hippocampal loss or change in ADAS-Cog
scores) between a treated and placebo group are outlined in the
appendix. All statistical calculations were conducted using R (the
R Project for Statistical Computing; http://www.r-project.org/).
Results
Data at baseline
Demographics and clinical data of the subjects at baseline are
summarized in Table 1. The groups were comparable in age
(P=0.2) and sex distribution (P=0.2, by 
2), but had markedly
different MMSE, ADAS-Cog and CDR scores, as expected (all
P50.001). While mild cognitive impairment and Alzheimer’s dis-
ease subjects had similar GDS scores (P=0.5), their scores were
both markedly higher than those of normal subjects (P50.001).
Mild cognitive impairment and Alzheimer’s disease patients also
had more than 2-fold higher rates of ApoE4 carriers than the
normal subjects (P50.001, by 
2). Estimations of hippocampal
volumes (in cubic millimetre, left and right averaged) at baseline
are listed in Table 2 for each group. As expected, Alzheimer’s dis-
ease patients had smaller hippocampal volumes than mild cognitive
impairment subjects (P50.0001) and both had smaller volumes
than normal subjects (P50.0001). Smaller baseline volumes were
signiﬁcantly associated with age (P50.01) in each group.
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Differences in rates between the left and right hippocampus were
not signiﬁcant (P40.2) and therefore the values were averaged.
Individual trajectories of hippocampal volume changes as a func-
tion of time are depicted in Fig. 1 for one-third of the subjects,
randomly selected. The thick solid line in each panel represents
the mean change in each respective group. This indicates that
Alzheimer’s disease patients had on average a smaller hippo-
campus and greater volume loss over time than normal subjects,
whereas mild cognitive impairment patients had intermediate
values between Alzheimer’s disease and normal. Table 2 lists the
estimated rates of hippocampal volume loss (in cublic millimetre/
year) for each group, separately for 0–6m, 6–12m and 0–12m
scan intervals. The rates of volume loss are also given in annual-
ized percentage change relative to baseline for comparison with
other publications. The rates are adjusted for subject age at
baseline. At 0–6m, hippocampal loss in mild cognitive impair-
ment and Alzheimer’s disease was already highly signiﬁcant
(P50.0001), whereas the loss in normal became signiﬁcant in
the 0–12m interval only (P=0.005). In general, the estimations
of hippocampal loss were more robust from measurements over
the 0–12m interval than over 0–6m and 6–12m, as indicated by
smaller standard errors and correspondingly higher signiﬁcance
levels. For all scan intervals, Alzheimer’s disease patients had a
markedly higher average rate of hippocampal loss than normal
subjects, whereas mild cognitive impairment patients had an inter-
mediate rate between Alzheimer’s disease and normal. There was
no signiﬁcant age by atrophy rates interaction for any group.
Given the number of subjects in this study, e.g. mild cognitive
impairment, the minimum detectable difference in atrophy rates
was 25mm
3/year at 80% power (=0.05). Neither baseline
volume nor rates were signiﬁcantly associated with severity of
depression (P=0.8).
For comparison, rates derived from an analysis using the
Markov chain approach, in which the observations from scan
interval 0–6m were explicitly used to estimate the rates in the
6–12m interval are also listed in Table 2. Compared to the regular
analysis of 6–12m data, the Markov chain approach yielded mark-
edly smaller random variations in addition to smaller standard
errors in rates. The inclusion of the 0–6m data made a signiﬁcant
contribution to the estimation of rates from the 6–12m data for all
groups [normal: likelihood ratio (LR)=32.7; mild cognitive impair-
ment: LR=46.7; Alzheimer’s disease: LR=36.3; all P50.0001].
We further tested whether the rates of hippocampal loss accel-
erated. The box-and-whisker plots in Fig. 2 depict the change of
hippocampal loss between 0–6 and 6–12m scan intervals by
group. In both mild cognitive impairment and Alzheimer’s disease
patients, the rates of hippocampal loss accelerated (P=0.0001)
but not in normal subjects (P=0.2). Based on a quadratic expan-
sion of time in the constant rate model, the hippocampal loss
accelerated by 26.54.5mm
3/year
2 in Alzheimer’s disease and
12.13.2mm
3/year
2 in mild cognitive impairment, equivalent to
Table 2 Hippocampal baseline volumes and rates of volume loss by group for different MRI scan intervals
Normal Mild cognitive impairment Alzheimer’s disease
Baseline [mm
3] 213325 (279) 184623 (348) 163134 (330)
Rates [mm
3/year]
0–6 month 19.717.0 [–89 to 51] (74) –37.710.6
 [–144 to 74] (63) –53.515.6
 [–152 to 62] (59)
6–12 month 8.321.7 [105 to 78] (85) 54.211.8
 [242 to 82] (60) 91.318.2
 [207 to 63] (62)
6–12 month
a 6.718.1 (74) 56.19.8
 (53) 93.015.0
 (50)
0–12 month 17.310.5
# [97 to 53] (80) 47.56.5
 [153 to 79] (65) 72.09.0
 [162 to 50] (56)
Percent change/year
b
0–6 month 0.90.8 2.00.6
 3.30.9

6–12 month 0.41.0 2.90.6
 5.61.1

6–12 month
a 0.30.8 3.00.5
 5.70.9

0–12 month 0.80.5
# 2.60.3
 4.40.6

a Using 0–6 months as prior and a Markov chain model for analysis.
b Percent volume change relative to baseline volume.
P50.0001;
#P=0.005.
Listed are meanSE; max/min rates in square brackets; random effect standard deviation in round brackets.
Figure 1 Individual trajectories of hippocampal volume change
from one-third of the subjects, randomly selected. The thick
black lines indicate the mean trajectory of each group.
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2 and 0.60.2%/year
2, respectively, relative to
baseline volume.
Correlations between rates of volume
loss and cognitive decline
The rates of ADAS-Cog (log transformed) correlated with the rates
of hippocampal loss in Alzheimer’s disease and mild cognitive
impairment patients (r=0.27; P=0.0005 by Spearman rank).
Similarly, the rates of change in MMSE (log transformed) corre-
lated with the rates of hippocampal loss in Alzheimer’s disease and
mild cognitive impairment patients (r=0.18, P=0.04 by Spearman
rank).
ApoE proﬁle and modulations of rates
of hippocampal loss
The effect of ApoE on rates of hippocampal loss is depicted in
Fig. 3. Presence of the ApoE4 gene was generally associated
with higher rates of hippocampal loss (LR=4.4; P=0.03) and
smaller baseline volumes (LR=27.2; P50.0001). The ApoE4
effect on rates was dominated by Alzheimer’s disease patients
with ApoE4, who lost on average 23.48.4mm
3/year
(1.40.5%/year loss relative to baseline volume) more hippo-
campal volume than patients not carrying ApoE4 (LR=7.8;
P=0.005), irrespective of the severity of cognitive impairments
(based on ADAS-Cog). A direct comparison between e3/3 with
e3/4 carriers (i.e. excluding those with alleles e2/2, e2/3, e2/4
and e4/4) yielded virtually, the same result. We also explored
the dose effect of ApoE4 on hippocampal loss rates by compar-
ing e3/4 and e4/4 carriers (e2/4 carriers were not considered
because there were only three) but found no signiﬁcant effect.
Interrelationships between explanatory variables (ApoE, age,
ADAS-Cog) for rates of volume loss were weak (r50.2 for all).
In normal and mild cognitive impairment subjects, ApoE4 was
not signiﬁcantly associated with higher hippocampal loss rates
(P=0.9).
Rates of hippocampal loss and CSF
biomarkers concentrations
We also tested if the rates of hippocampal loss are correlated with
the concentration of CSF biomarkers Ab1–42, t-tau and p-tau at
baseline on a smaller sample (68 normal, 109 mild cognitive
impairment, 53 Alzheimer’s disease), whose biomarker data
were available at the time of the analysis. The baseline concentra-
tions (in pg/ml) of Ab1–42, t-tau and p-tau, respectively, were:
13739/11959/4017 in Alzheimer’s disease; 15954/
10452/3617 in mild cognitive impairment; and 21154/
7030/2514 in control. Overall, higher rates of hippocam-
pal loss were associated with decreased Ab1–42 concentration
(P50.01). The effect remained signiﬁcant after accounting for
ApoE genotype and level of cognitive impairment. Among the
explanatory variables for rates of volume loss, Ab1–42 and ApoE
were the only ones that had a signiﬁcant interrelationship
(r=0.58) with Ab1–42 contributing 1.5 times as much to the
variability of hippocampus atrophy rates than ApoE. The link
between Ab1–42 and hippocampal rates was driven by mild
cognitive impairment subjects, who lost on average
0.30.1mm
3/year hippocampal volume per pg/ml decrease
of Ab1–42 in CSF (P=0.04), equivalent to 0.020.01%/year
loss relative to baseline volume.
No signiﬁcant correlation between Ab1–42 and MRI was seen
in the Alzheimer’s disease (P=0.1) or normal group (P=0.5).
The regression plots in Fig. 4 depict the relationship between
rates of hippocampal loss and Ab1–42 concentration, separately
by group. Note, Ab1–42 concentration is plotted on a logarithmic
scale to stabilize the regressions by imposing a more uniform
distribution of the Ab1–42 values. In contrast to Ab1–42, the cor-
relation between CSF t-tau concentrations and hippocampal loss
rates was only a trend (P=0.058) and this was limited to
Alzheimer’s disease patients. There were no signiﬁcant correla-
tions between CSF p-tau concentrations and hippocampal loss
rates in any group.
Figure 3 Rates of hippocampal volume loss in carriers and
non-carriers of ApoE4.
Figure 2 Accelerations of rates of hippocampal volume loss.
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To determine the power of MRI in detecting effects on hippo-
campal volume loss over time we estimated the sample size
needed in a hypothetical treatment trial to measure a 25%
slowing in the rate of volume loss with 90% conﬁdence and
=0.05 signiﬁcance. We considered two separate strategies to
maximize power: in the ﬁrst strategy, we considered increasing
either the inter-scan interval from 0–6 to 0–12m or alternatively
increasing the number of MRI scans from two to three, i.e. scan-
ning at 0–6–12m. In the second strategy, we considered gaining
power by using prior information, such as exploiting correlations
between successive observations by Markov chain analysis and/or
by considering the ApoE4 proﬁle and Ab1–42 concentration in CSF
at baseline. The powers, expressed as sample sizes estimations of
the different strategies are summarized in Table 3, separately for
Alzheimer’s disease and mild cognitive impairment. This shows
in general that prolonging the inter-scan interval from 6 to
12 months reduced the sample size, as expected. The use of
three time-points instead of two lowered the sample size for
mild cognitive impairment and accounting for ApoE4 lowered
the sample size for Alzheimer’s disease. By far the most effective
reduction of sample size in this context was accomplished by
exploiting correlations between observations, i.e. using Markov
chain analysis. Accounting for ApoE4 status in the Markov chain
analysis further reduced the sample size for Alzheimer’s disease
to ﬁnally 86 patients and for mild cognitive impairment to 341
patients per arm. Including the Ab1–42 concentration in CSF at
baseline did not lead to additional improvements. We also con-
sidered the rate of dropouts in power estimations of three versus
two scans. For a Markov chain analysis, which requires at least
three scans, the dropout rate has to exceed roughly 20% before
the power beneﬁt compared to a conventional mixed effects
analysis with only two scans is lost. In contrast to Markov chain,
a conventional mixed effects analysis with three scans holds a
slight advantage over one with two scans as long as the dropout
is less than about 5%. In this study, the dropout rate between two
and three scans was about 5%.
For comparison, the sample sizes based on rates of ADAS-Cog
or MMSE are also listed in Table 3 for various study scenarios. In
contrast to MRI, there was no beneﬁt for sample size of ADAS-
Cog and MMSE rates from using the Markov chain approach.
Variability between MRI sites
Lastly, we determined the extent to which MRI performed at
multiple centres increases the variability compared with MRI at
individual centres. Figure 5 depicts the variability of random
effects errors in measurements of hippocampal rates between
the centres. Data are shown for 13 MRI centres, which had
MRI data collected at three time-points in at least seven mild
cognitive impairment patients at the time this report was written.
For comparison, the variability of random effects errors when all
47 ADNI centres were included is indicated by the black bar on
the far right. Overall, variability of MRI performance between the
centres was not signiﬁcant (P=0.5).
Discussion
Our main ﬁndings are: (i) in mild cognitive impairment and
Alzheimer’s disease, progression of hippocampal loss was detected
over 6 months and accelerated over 1 year, whereas in the normal
group hippocampal loss was detected over 1 year with no indica-
tion of acceleration; (ii) ApoE4 was associated with higher rates
of hippocampal loss in Alzheimer’s disease patients, irrespective
of their level of cognitive impairments; (iii) higher rates of hippo-
campal loss correlated with a lower concentration of CSF Ab1–42,
Figure 4 Associations between annual rates of hippocampal
volume loss and Ab1–42 concentration in CSF.
Table 3 Estimations of sample size per arm for a
hypothetical trial to detect 25% rate slowing with
90% power and a=0.05
Study design Alzheimer’s
disease
Mild cognitive
impairment
MRI Hippocampal volume
Two scans, 0–6 m
a 462 949
Two scans, 0–12 m
a 252 698
Three scans, 0–6–12 m
a 255 673
Three scans+ApoE4
b 196 672
Three scans+MC
c 140 383
Three scans+MC+ApoE4
d 86 341
ADAS-Cog
e
Two tests, 0–6m 745 4663
Two tests, 0–12m 814 9350
Three tests, 0–6–12m 569 8354
MMSE
e
Two tests, 0–6m 1280 6300
Two tests, 0–12m 1083 3900
Three tests, 0–6–12m 780 3353
a Based on MRI scans at baseline (0m), 6 (6m) and/or 12 months (12m).
b Accounting for ApoE4 proﬁle.
c Using the Markov chain approach (see text for details).
d Using ApoE4 and Markov chain together.
e Using the Markov chain approach did not signiﬁcantly improve sample size.
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impairment patients. Furthermore, we showed that the power of
measuring hippocampal change can be improved by exploiting
intrinsic correlations between successive MRI observations. In
addition, we showed that site-to-site variations in MRI can
effectively be brought to levels similar to single site settings
using the rigorous methods of the ADNI.
We found signiﬁcant hippocampal volume loss in mild cognitive
impairment and Alzheimer’s disease over only 6 months. All but
one other MRI study reported hippocampal loss over such a short
period and only for Alzheimer’s disease (Barnes et al., 2008b).
Furthermore, the prior study conducted MRI at a single centre
only, yielding no conclusions for multicentre trials. Nonetheless,
our results in Alzheimer’s disease and those from this single
centre study are intriguingly similar. Our results (average of 0–6
and 6–12 months rate values) expressed as percentage annual
change yield 4.5% hippocampal loss in Alzheimer’s disease
(2–6% within 95% CI) compared with the range 4.35–5.04%
that the single centre study reported. For mild cognitive impair-
ment, our results over 6 months yield 2.5% annualized hippo-
campal loss (2.0–3.3% within 95% CI), in good agreement with
reports of most other longitudinal MRI studies of mild cognitive
impairment (Jack et al., 2000; Du et al., 2004; Fox et al., 2005;
Hashimoto et al., 2005) that used much longer scan intervals,
including two multicentre trials (Jack Jr et al., 2008b; van de Pol
et al., 2007). The rates of hippocampal loss in our study are also
within the range found in a large meta-analysis (Barnes et al.,
2008a). It is furthermore re-afﬁrming that our results obtained
with a semi-automated method for tracing the hippocampus are
comparable with those that employed entirely manual methods
(Jack et al., 2000). Taken together, our results imply that an
assessment of hippocampal loss over 6 months is possible and
this extends to multicentre trials. However, measurement power
is clearly sacriﬁced at shorter intervals as indicated by the larger
standard errors for rates from measurements over 6 months
compared to those over 12 months. Limited spatial resolution of
MRI is likely the main reason for incurring errors at shorter
scan intervals. Therefore, longitudinal studies of hippocampal loss
should beneﬁt from higher MRI resolution, if it can be afforded.
Since a quarter of the participants in the ADNI will also be scanned
at 3T parallel to 1.5T but at 20% higher resolution, the impact of
image resolution on the power to measure brain volume loss can
ultimately been tested. It is surprising that the rate of volume
loss in mild cognitive impairment between 6 and 12 months is
similar to that in Alzheimer’s disease between 0 and 6 months,
though some mild cognitive impairment subjects are destined
to develop Alzheimer’s disease. A possible explanation for this
observation is that accelerated volume loss over time is a more
prominent feature that separates Alzheimer’s disease from mild
cognitive impairment than constant volume loss. In addition, the
annual percentage change from baseline is lower in mild cogni-
tive impairment than in Alzheimer’s disease.
The rates of hippocampal loss also correlated with rates of cog-
nitive decline. In general, Alzheimer’s disease and mild cognitive
impairment patients with high hippocampal rates also had rapidly
increasing ADAS-Cog scores, while the correlation with MMSE
scores was weaker. It is possible that cognitive tests that are
more speciﬁc for hippocampal function show stronger correla-
tions with MRI. Additional analyses that are beyond the scope
of this report are warranted to further explore the cognitive
correlates of hippocampal volume changes.
We also found signiﬁcant hippocampal loss in the normal group
over 1 year, in agreement with several prior MRI studies (Fox and
Schott, 2004; Du et al., 2005; Jack et al., 2005) as well as with
autopsy ﬁndings of neuronal loss in the ageing hippocampus
(West, 1993; Simic et al., 1997). However, to determine if
hippocampal loss in normal subjects is already an indication of
incipient Alzheimer’s disease or other pathologies affecting the
hippocampus requires clinical follow-up of the subjects to
determine their cognitive decline and ultimate development of
Alzheimer’s disease.
We found accelerated hippocampal loss in the mild cognitive
impairment and Alzheimer’s disease groups over a period of
1 year. Accelerated rates of hippocampal loss have previously
been reported for mild cognitive impairment (Jack et al., 2008c)
and for familial Alzheimer’s disease (Ridha et al., 2006), but over
periods that ranged from 2 to 5 years. Our ﬁnding is also con-
sistent with reports of accelerated loss of whole brain (Chan
et al., 2003; Carlson et al., 2008) and clinical studies of accel-
erated cognitive decline in mild cognitive impairment and early
Alzheimer’s disease (Mungas et al., 2005; Boyle et al., 2006).
To estimate accelerated hippocampal loss, we used a simple
quadratic expansion for change that may not accurately reﬂect
the true progression of hippocampal loss. Observations at much
more than three time- points, as planned in the ADNI, should
help to better characterize the trajectory of accelerated loss.
Nonetheless, the ﬁnding of accelerating hippocampal loss is impor-
tant for understanding the natural history of Alzheimer’s disease
and emphasizes the need for early diagnosis and therapeutic inter-
vention. The fact that we were able to detect accelerated rates
over 1-year period has consequences for longitudinal MRI studies
with only two time-points. First, such studies may overestimate
or underestimate hippocampal loss rates since two serial mea-
surements are indifferent to accelerations. Second, the ability to
detect differences may be limited if accelerations vary among
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Figure 5 Variability in measuring hippocampal rates between
MRI centres. Centres are coded by numbers.
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over 3 years to provide more information on longitudinal change.
Our ﬁnding that ApoE4 is a modulator of hippocampal loss
rates is consistent with other MRI studies (Moffat et al., 2000;
Cohen et al., 2001; Jack Jr et al., 2008b; van de Pol et al., 2007),
but some studies found no ApoE effect (Laakso et al., 2000).
Furthermore, whereas others reported an ApoE4 effect on hippo-
campal rates for mild cognitive impairment (Jack Jr et al., 2008b),
we found it limited to Alzheimer’s disease. In a recent cross-
sectional MRI study of 676 ADNI subjects using tensor-based
morphometry (Hua et al., 2008), over half of the Alzheimer’s
disease and mild cognitive impairment subjects carried the
ApoE4 gene, and they showed greater hippocampal and temporal
lobe deﬁcits than non-carriers. Around one-sixth of the controls
carried the protective ApoE2 gene and showed reduced ventricu-
lar expansion, perhaps reﬂecting a lesser degree of overall brain
atrophy. We did not ﬁnd a signiﬁcant dose effect of ApoE4
on hippocampal loss rates in contrast to another study (van de
Pol et al., 2007). Given our sample size of 226 mild cognitive
impairment patients and 10% within subject variation, we
should have been able to detect about 5% difference between
carriers and non-carriers with 80% power and at =0.05 signiﬁ-
cance. One possible explanation for the discrepant ApoE ﬁndings
in mild cognitive impairment is the notorious heterogeneity of this
group, which—in absence of histological evidence for Alzheimer’s
disease pathology—may include other causes of cognitive com-
plaints, such as mood disorders or cerebrovascular disease that
both can impact the hippocampus (Lloyd et al., 2004; Mungas
et al., 2005). Nonetheless, our ﬁnding suggests that presence of
ApoE4 exacerbates the impact of Alzheimer’s disease on the
hippocampus. Alzheimer’s disease cohorts of future therapeutic
trials could be enriched by including speciﬁcally patients who
carry ApoE4 and are likely to have small hippocampi and high
rates of hippocampal loss.
We also found a marked association between higher rates of
hippocampal loss and decreased concentration of Ab1–42 in CSF,
predominantly in the mild cognitive impairment group, whereas
for t-tau we found only a trend in the Alzheimer’s disease
group and for p-tau no signiﬁcant association in any of the
groups. Ab1–42 and tau concentrations in CSF represent the
earliest and most intensely studied biochemical markers of
Alzheimer’s disease (Frank et al., 2003; Grossman et al., 2005).
How well these biomarkers reﬂect an autopsy-conﬁrmed
dementia diagnosis has intensely been studied (Clark et al.,
2003). Both proteins are directly linked to the two hallmark
lesions of Alzheimer’s disease, Ab1–42 with amyloid plaques and
tau (t-tau and p-tau) with neuroﬁbrillary tangles (Clark et al.,
2006). Numerous studies have documented reduced Ab1–42
and increased p-tau in CSF in Alzheimer’s disease patients (see
Clark et al., 2008 for review). But only two prior MRI studies
compared CSF biomarkers with hippocampal loss rates in a small
pool of subjects. Consistent with our ﬁndings, de Leon et al.
(2006) reported greater hippocampal loss with greater Ab1–42
decrease. In contrast to our results in mild cognitive impairment,
they also found signiﬁcantly greater hippocampal loss with
increased p-tau but their study included only nine mild cognitive
impairment subjects. Hampel et al. (2005), studying Alzheimer’s
disease, found increased hippocampal rates correlated with
increased p-tau in 22 patients, while we found only a trend.
Our ﬁnding that increased rates of hippocampal loss correlate
with decreased Ab1–42 in a large number of mild cognitive impair-
ment patients is particularly interesting, because Ab1–42 is directly
related to Alzheimer’s disease pathology. It is also important to
note that the association between high hippocampal rates and
reduced CSF Ab1–42 was independent of the ApoE proﬁle, imply-
ing that CSF Ab1-42 levels and rates of hippocampal loss are
directly linked. The results support the view that high rates
of hippocampal loss in mild cognitive impairment indicate
Alzheimer’s disease pathology. Since the hippocampus is spared
from early amyloid burden (Silbert et al., 2003), the correlation
between high rates of hippocampal loss and decreased CSF
Ab1–42, further implies that the two measures provide compli-
mentary information about the presence of Alzheimer’s disease
pathology. However, the diagnostic value of the measures used
together remains unclear, because each measure can also change
in other pathological conditions, such as Lewy body dementia
(Clark et al., 2003).
Using a Markov chain model to analyse hippocampal change,
we showed that intrinsic correlations between successive MRI
observations exist and can be exploited to reduce within subject
variability and consequently improve measurement power. The
impact on power was substantial despite the fact that we per-
formed hippocampal tracing independently for each time-point.
The results imply that image processing algorithms that utilize
correlations between observations, i.e. by using the hippocampal
boundaries from past MRI scans as priors for tracing the bound-
aries in a new MRI scan, should be superior to those algorithms
that do not employ priors. However, the approach also has limi-
tations, as our results indicate. For instance, the Markov chain
approach did not beneﬁt the analysis of data from the normal
group as much as the analysis of the mild cognitive impairment
or Alzheimer’s disease group, presumably because errors in asses-
sing the small volume changes in normal subjects were random
and dominated systematic biological changes. At the other end,
the beneﬁt of a Markov chain analysis was also less effective
for Alzheimer’s disease than for mild cognitive impairment data,
presumably because the volume changes in Alzheimer’s disease
patients were sufﬁciently large to incur fewer errors to begin
with. Since each subject in the ADNI study will ultimately have
multiple successive MRI scans, it will be possible to evaluate the
beneﬁt of analysis using Markov chain models in more detail.
Our results demonstrate that for studies of hippocampal rates
site-to-site variations in MRI can effectively be controlled using
the rigorous methods of the ADNI. The result is important,
because multiple MRI centre settings are indispensable for large
studies, such as clinical trials with hundreds of subjects. Since
additional variability is inevitably introduced in multiple MRI site
settings compared to a single site setting, which is more common
for investigational study use, we were also interested in comparing
the powers of multisite and single site studies to detect a certain
level of atrophy rates. Based on the site-to-site variations shown
in Fig. 5, we estimated that 80% power of this multisite study
of 47 MRI sites translates roughly into 87% power if the same
study with the same population and number of subjects was
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Fig. 5) with the least variability of all sites. Although the result
implies a beneﬁt in power from a single site, as expected, the
gain overall seems small, especially if one considers that the
other participating sites in this study have smaller beneﬁt
margins since they show greater variability than the ‘best’ single
site. In summary, the result attests to the effectiveness of the
rigorous control methods developed by the ADNI. Our power
estimations also show that MRI consistently provides greater
power to measure progression than cognitive tests, such as
ADAS-Cog or MMSE. Furthermore, some additional power can
be gained by measuring hippocampal change at more time-
points and by considering whether patients carry ApoE4.
Several limitations ought to be mentioned: First, mild cognitive
impairment and normal subjects have not been followed long
enough to determine the incidence of incipient Alzheimer’s dis-
ease in each respective group. The rates and accelerations for
these groups may therefore be biased toward higher values if
many subjects with preclinical Alzheimer’s disease were included.
Furthermore, clinical criteria are always imperfect and some
subjects in a mild stage of disease can be difﬁcult to classify.
However, the ADNI utilizes the rigorous diagnostic criteria of ther-
apeutic trials which are one of the best available. The chance of
a major bias of the results due to clinical misdiagnosis is small.
Second, white matter lesions, an indication for cerebrovascular
disease, were not accounted for. As previous studies showed
white matter lesions can be associated with hippocampal atrophy
(Fein et al., 2000), our results could at least in part be related
to vascular disease. Third, since the algorithm to measure the
hippocampus utilizes information from the rest of the brain,
changes in other brain regions as well as image artefacts could
have mimicked hippocampal variations. Completely manual mea-
surements of the hippocampus might therefore lead to a different
outcome.
In conclusion, the demonstration of hippocampal loss in mild
cognitive impairment and Alzheimer’s disease patients over
6 months and accelerated loss over 12 months illustrates the
power of MRI to track morphological brain changes over time
in a large multisite setting. Furthermore, our ﬁnding of higher
hippocampal loss in presence of ApoE4 and reduced CSFAb1–42
supports the concept that increased hippocampal loss is an
indicator of Alzheimer’s disease pathology and a potential
marker to assess therapeutic interventions in Alzheimer’s disease.
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Acknowledgements
We are indebted to Drs Laurel Beckett, UC San Diego, Danielle
Harvey, UC Davis and John Kornak, UC San Francisco for statis-
tical support. Data collection and sharing for this project was
funded by the Alzheimer’s Disease Neuroimaging Initiative
(ADNI; Principal Investigator: M.W.).
Funding
The ADNI is funded by the National Institute on Aging, the
National Institute of Biomedical Imaging and Bioengineering
(NIBIB), and through generous contributions from the following:
Pﬁzer Inc., Wyeth Research, Bristol-Myers Squibb, Eli Lilly and
Company, GlaxoSmithKline, Merck & Co. Inc., AstraZeneca AB,
Novartis Pharmaceuticals Corporation, Alzheimer’s Association,
Eisai Global Clinical Development, Elan Corporation plc, Forest
Laboratories, Innogenetics, NV, Ghent, Belgium, and the Institute
for the Study of Aging, with participation from the U.S. Food and
Drug Administration. Industry partnerships are coordinated through
the Foundation for the National Institutes of Health. The grantee
organization is the Northern California Institute for Research and
Education, and the study is coordinated by the Alzheimer’s Disease
Cooperative Study at the University of California, San Diego. The
ADNI data are disseminated by the Laboratory of Neuro Imaging
at the University of California, Los Angeles. Funding to pay the
Open Access publication charges for this article was provided by
the Alzheimer’s Disease Neuroimaging Initiative National Institutes
of Health (U01 AG024904 to M.W.).
References
Barnes J, Bartlett JW, van de Pol LA, Loy CT, Scahill RI, Frost C,et al. A meta-
analysis of hippocampal atrophy rates in Alzheimer’s disease. Neurobiol
Aging 2008a [Epub ahead of print; doi:10.1016/j.neurobiolaging.
2008.01.010].
Barnes J, Scahill RI, Frost C, Schott JM, Rossor MN, Fox NC. Increased
hippocampal atrophy rates in Alzheimer’s disease over 6 months using
serial MR imaging. Neurobiol Aging 2008b; 29: 1199–203.
Boyle PA, Wilson RS, Aggarwal NT, Tang Y, Bennett DA. Mild cognitive
impairment: risk of Alzheimer disease and rate of cognitive decline.
Neurology 2006; 67: 441–5.
Braak H, Braak E. Evolution of neuronal changes in the course of
Alzheimer’s disease. J Neural Transm Suppl 1998; 53: 127–40.
Carlson NE, Moore MM, Dame A, Howieson D, Silbert LC, Quinn JF,
et al. Trajectories of brain loss in aging and the development of
cognitive impairment. Neurology 2008; 70: 828–33.
Chan D, Janssen JC, Whitwell JL, Watt HC, Jenkins R, Frost C, et al. Change
in rates of cerebral atrophy over time in early-onset Alzheimer’s disease:
longitudinal MRI study. Lancet 2003; 362: 1121–2.
Christensen GE, Joshi SC, Miller MI. Volumetric transformation of brain
anatomy. IEEE Trans Med Imaging 1997; 16: 864–77.
Clark CM, Davatzikos C, Borthakur A, Newberg A, Leight S, Lee VM,
et al. Biomarkers for early detection of Alzheimer pathology.
Neurosignals 2008; 16: 11–8.
Clark CM, Pratico D, Shaw L, Leight S, Xie S, Gu A, et al. Biochemical bio-
markers of late-life dementia. Alzheimer’s & Dementia 2006; 2: 287–93.
Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, et al.
Cerebrospinal ﬂuid tau and beta-amyloid: how well do these bio-
markers reﬂect autopsy-conﬁrmed dementia diagnoses? Arch Neurol
2003; 60: 1696–702.
Cohen RM, Small C, Lalonde F, Friz J, Sunderland T. Effect of apolipo-
protein E genotype on hippocampal volume loss in aging healthy
women. Neurology 2001; 57: 2223–8.
de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al.
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild
cognitive impairment. Neurobiol Aging 2006; 27: 394–401.
Du AT, Schuff N, Chao LL, Kornak J, Jagust WJ, Kramer JH, et al. White
matter lesions are associated with cortical atrophy more than ento-
rhinal and hippocampal atrophy. Neurobiol Aging 2005; 26: 553–9.
1076 | Brain 2009: 132; 1067–1077 N. Schuff et al.Du AT, Schuff N, Kramer JH, Ganzer S, Zhu XP, Jagust WJ, et al. Higher
atrophy rate of entorhinal cortex than hippocampus in Alzheimer’s
disease. Neurology 2004; 62: 422–7.
Fein G, Di SV, Tanabe J, Cardenas V, Weiner MW, Jagust WJ, et al.
Hippocampal and cortical atrophy predict dementia in subcortical ische-
mic vascular disease [In Process Citation]. Neurology 2000; 55: 1626–35.
Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al.
Global prevalence of dementia: a Delphi consensus study. Lancet
2005; 366: 2112–7.
Fjell AM, Walhovd KB, Amlien I, Bjornerud A, Reinvang I, Gjerstad L, et al.
Morphometric changes in the episodic memory network and tau patho-
logic features correlate with memory performance in patients with mild
cognitive impairment. AJNR Am J Neuroradiol 2008; 29: 1183–9.
Folstein MF, Folstein SE, McHugh PR. ‘‘Mini-mental state’’. A practical
method for grading the cognitive state of patients for the clinician.
J Psychiatr Res 1975; 12: 189–98.
Fox NC, Black RS, Gilman S, Rossor MN, Grifﬁth SG, Jenkins L, et al.
Effects of Abeta immunization (AN1792) on MRI measures of cerebral
volume in Alzheimer disease. Neurology 2005; 64: 1563–72.
Fox NC, Schott JM. Imaging cerebral atrophy: normal ageing to
Alzheimer’s disease. Lancet 2004; 363: 392–4.
Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, Mehta PD, et al.
Biological markers for therapeutic trials in Alzheimer’s disease.
Proceedings of the biological markers working group; NIA initiative on
neuroimaging in Alzheimer’s disease. Neurobiol Aging 2003; 24: 521–36.
Grossman M, Farmer J, Leight S, Work M, Moore P, Van Deerlin V,
et al. Cerebrospinal ﬂuid proﬁle in frontotemporal dementia and
Alzheimer’s disease. Ann Neurol 2005; 57: 721–9.
Hampel H, Burger K, Pruessner JC, Zinkowski R, DeBernardis J,
Kerkman D, et al. Correlation of cerebrospinal ﬂuid levels of tau
protein phosphorylated at threonine 231 with rates of hippocampal
atrophy in Alzheimer disease. Arch Neurol 2005; 62: 770–3.
Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E. Does
donepezil treatment slow the progression of hippocampal atrophy in
patients with Alzheimer’s disease? Am J Psychiatry 2005; 162: 676–82.
Hsu YY, Schuff N, Du AT, Mark K, Zhu X, Hardin D, et al. Comparison
of automated and manual MRI volumetry of hippocampus in normal
aging and dementia. J Magn Reson Imaging 2002; 16: 305–10.
Hua X, Leow AD, Parikshak N, Lee S, Chiang MC, Toga AW, et al.
Tensor-based morphometry as a neuroimaging biomarker for
Alzheimer’s disease: An MRI study of 676 Alzheimer’s disease, mild
cognitive impairment, and normal subjects. Neuroimage 2008; 43:
458–69.
Jack CR Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D,
et al. The Alzheimer’s Disease Neuroimaging Initiative (ADNI): MRI
methods. J Magn Reson Imaging 2008a; 27: 685–91.
Jack CR Jr, Petersen RC, Grundman M, Jin S, Gamst A, Ward CP, et al.
Longitudinal MRI ﬁndings from the vitamin E and Donepezil treatment
study for mild cognitive impairment. Neurobiol Aging 2008b; 29: 1285–95.
Jack CR Jr, Petersen RC, Xu Y, O’Brien PC, Smith GE, Ivnik RJ, et al.
Rates of hippocampal atrophy correlate with change in clinical status
in aging and Alzheimer’s disease. Neurology 2000; 55: 484–9.
Jack CR Jr, Shiung MM, Weigand SD, O’Brien PC, Gunter JL, Boeve BF,
et al. Brain atrophy rates predict subsequent clinical conversion in
normal elderly and amnestic mild cognitive impairment. Neurology
2005; 65: 1227–31.
Jack CR Jr, Weigand SD, Shiung MM, Przybelski SA, O’Brien PC,
Gunter JL, et al. Atrophy rates accelerate in amnestic mild cognitive
impairment. Neurology 2008c; 70: 1740–52.
Jack C Jr, Petersen RC, Xu Y, O’Brien PC, Smith GE, Ivnik RJ, et al. Rates
of Hippocampal Atrophy in Normal Aging, Mild Cognitive Impairment,
and Alzheimer’s Disease. Neurology 2000; 55: 484–9.
Jack CR Jr, Shiung MM, Gunter JL. Comparison of different MRI brain
atrophy rate measures with clinical disease progression in Alzheimer’s
disease. Neurology 2004; 62: 591–600.
Jack C Jr, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K,
et al. MRI as a Biomarker of Disease Progression in a Therapeutic Trial
of Milameline fo Alzheimer’s. Neurology 2003; 60: 253–60.
Laakso MP, Lehtovirta M, Partanen K, Riekkinen PJ, Soininen H.
Hippocampus in Alzheimer’s disease: a 3-year follow-up MRI study.
Biol Psychiatry 2000; 47: 557–61.
Leow Alzheimer’s disease, Klunder Alzheimer’s disease, Jack CR Jr,
Toga AW, Dale AM, Bernstein MA, et al. Longitudinal stability of
MRI for mapping brain change using tensor-based morphometry.
Neuroimage 2006; 31: 627–40.
Lloyd AJ, Ferrier IN, Barber R, Gholkar A, Young AH, O’Brien JT.
Hippocampal volume change in depression: late- and early-onset
illness compared. Br J Psychiatry 2004; 184: 488–95.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM.
Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-
Alzheimer’s diseaseRDA Work Group under the auspices of
Department of Health and Human Services Task Force on
Alzheimer’s disease. Neurology 1984; 34: 939–44.
Moffat SD, Szekely CA, Zonderman AB, Kabani NJ, Resnick SM.
Longitudinal change in hippocampal volume as a function of apolipo-
protein E genotype. Neurology 2000; 55: 134–6.
Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M,
et al. Development of cognitive instruments for use in clinical trials of
antidementia drugs: additions to the Alzheimer’s disease Assessment
Scale that broaden its scope. The Alzheimer’s Disease Cooperative
Study. Alzheimer Dis Assoc Disord 1997; 11 (Suppl 2): S13–21.
Morris JC. The Clinical Dementia Rating (CDR): current version and
scoring rules [see comments]. Neurology 1993; 43: 2412–4.
The Alzheimer’s disease neuroimaging initiative. Neuroimaging Clin N
Am 2005; 15: 869–77xi–xii.
Mungas D, Harvey D, Reed BR, Jagust WJ, DeCarli C, Beckett L, et al.
Longitudinal volumetric MRI change and rate of cognitive decline.
Neurology 2005; 65: 565–71.
Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, et al.
Tracking atrophy progression in familial Alzheimer’s disease: a serial
MRI study. Lancet Neurol 2006; 5: 828–34.
Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ. Biomarkers
of neurodegeneration for diagnosis and monitoring therapeutics.
Nat Rev Drug Discov 2007; 6: 295–303.
Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen P,
Petersen RC, et al. and the ADNI Investigators. Cerebrospinal ﬂuid
biomarker signature in Alzheimer’s Disease Neuroimaging Initiative
(ADNI) subjects. Ann Neurol 2009 (in press).
Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, Murdoch G,
et al. Changes in premorbid brain volume predict Alzheimer’s disease
pathology. Neurology 2003; 61: 487–92.
Simic G, Kostovic I, Winblad B, Bogdanovic N. Volume and number of
neurons of the human hippocampal formation in normal aging and
Alzheimer’s disease. J Comp Neurol 1997; 379: 482–94.
Thompson PM, Hayashi KM, Dutton RA, Chiang MC, Leow
Alzheimer’s disease, Sowell ER, et al. Tracking Alzheimer’s disease.
Ann N Y Acad Sci 2007; 1097: 183–214.
de Pol LA, Hensel A, van der Flier WM, Visser P, Pijnenburg YA,
Barkhof F, et al. Hippocampal atrophy on MRI in frontotemporal
lobar degeneration and Alzheimer’s disease. J Neurol Neurosurg
Psychiatry 2005; 10: 1136.
de Pol LA, van der Flier WM, Korf ES, Fox NC, Barkhof F, Scheltens P.
Baseline predictors of rates of hippocampal atrophy in mild cognitive
impairment. Neurology 2007; 69: 1491–7.
Vanderstichele H, De Meyer G, Shapiro F, Engelborghs B, DeDeyn PP,
Shaw LM, et al. Alzheimer’s disease biomarkers: From concept to
clinical utility. In: Galimberti D, Scarpini E, editors. Biomarkers for
Early Diagnosis of Alzheimer s Disease. Hauppauge, NY: Nova
Scinece Publishers, Inc.; 2008. pp. 81–122.
West MJ. Regionally speciﬁc loss of neurons in the aging human hippo-
campus. Neurobiol Aging 1993; 14: 287–93.
Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al.
Development and validation of a geriatric depression screening scale:
a preliminary report. J Psychiatr Res 1982; 17: 37–49.
MRI of hippocampal volume loss in early Alzheimer’s disease Brain 2009: 132; 1067–1077 | 1077